IRLAB names Janne Backman board chair, replacing Carola Lemne

By Public Technologies
  • IRLAB Therapeutics named Jan-Fredrik “Janne” Backman chairman, succeeding Carola Lemne, who stepped down in September.
  • Backman was elected vice chairman at the 2026 annual general meeting.
  • He previously held strategy, marketing, and R&D program leadership roles at The Medicines Company.
  • Backman also held commercial positions at Merck Serono, AstraZeneca.
  • He has served as CEO of J.F.B Consulting AB, J.F.B Invest since 2016.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRLAB Therapeutics AB published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk